Back to the main directory
EarningsReview / Equity
- Amazon: The evidence is clear by BNP Paribas Exane
- On the road with OMV’s CEO by BNP Paribas Exane
- Pets at Home (PETS LN) by HSBC
- 2028 vision but all eyes on CoStar by BNP Paribas Exane
- Bigben - De bon augure by MidCap Partners
- INVEST SECURITIES – TME PHARMA : Financement de 2,7m€ pouvant aller jusqu'à 4,9m€ - ACHAT, OC 0,4€ vs 4,2€) by Invest Securities
- Bigben - A Good Omen by MidCap Partners
- Heliad - A german vc and growth equity investor by Edison Investment Research
- Shining The Light On The Backbone Of AI by BNP Paribas Exane
- An Under-The-Radar Play On AI/ML by BNP Paribas Exane
- Cellnex - A DISCIPLINED APPROACH IN CONTROLLING LEVERAGE by Equita Sim
- Generative AI: how they’re using it by BNP Paribas Exane
- AI a new era for AMD by BNP Paribas Exane
- What’s been going on in November? by BNP Paribas Exane
- Non material data changes by BNP Paribas Exane
- Green Shoots to Make a Salad by BNP Paribas Exane
- Boozt (Hold, TP: SEK100.00) - Record Black Week by DnB Markets
- Valuation update by DnB Markets
- Postcard from Piccadilly by BNP Paribas Exane
- Non-Tracked Channels Are Still on Track by BNP Paribas Exane
- GREENVOLT - 3Q23 EBITDA beat from project development; Buy by JB Capital Markets
- Strengthened view on SMR, unchanged concerns around SMS - CMD feedback by BNP Paribas Exane
- Aedas Homes - Weaker 2Q23 does not change our investment case; Buy by JB Capital Markets
- Preview COP 28: towards a bigger role for private financing? by Oddo BHF
- INVEST SECURITIES –BIGBEN : Rien de bien nouveau en dehors de NACON - ACHAT,OC 6,4€ vs 5,6€ by Invest Securities